A Study to Evaluate PT-523 in Patients With Refractory Leukemia
Status:
Withdrawn
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose
of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as
therapy in subjects with refractory leukemia.